These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Structural imaging markers for therapeutic trials in Alzheimer's disease. Fox NC; Kennedy J J Nutr Health Aging; 2009 Apr; 13(4):350-2. PubMed ID: 19300877 [No Abstract] [Full Text] [Related]
3. Neuroimaging outcomes in clinical trials in Alzheimer's disease. Frisoni GB; Delacourte A J Nutr Health Aging; 2009 Mar; 13(3):209-12. PubMed ID: 19262955 [TBL] [Abstract][Full Text] [Related]
4. Structural Magnetic Resonance Imaging Markers of Alzheimer's Disease and Its Retranslation to Rodent Models. Kincses ZT; Király A; Veréb D; Vécsei L J Alzheimers Dis; 2015; 47(2):277-90. PubMed ID: 26401552 [TBL] [Abstract][Full Text] [Related]
5. What we have learned from the Xaliproden Sanofi-aventis trials. Douillet P; Orgogozo JM J Nutr Health Aging; 2009 Apr; 13(4):365-6. PubMed ID: 19300882 [No Abstract] [Full Text] [Related]
6. Functional Magnetic Resonance Imaging in Alzheimer' Disease Drug Development. Holiga S; Abdulkadir A; Klöppel S; Dukart J Methods Mol Biol; 2018; 1750():159-163. PubMed ID: 29512071 [TBL] [Abstract][Full Text] [Related]
7. Alliance for aging research AD biomarkers work group: structural MRI. Jack CR Neurobiol Aging; 2011 Dec; 32 Suppl 1(0 1):S48-57. PubMed ID: 22078173 [TBL] [Abstract][Full Text] [Related]
8. Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities. Parent MJ; Zimmer ER; Shin M; Kang MS; Fonov VS; Mathieu A; Aliaga A; Kostikov A; Do Carmo S; Dea D; Poirier J; Soucy JP; Gauthier S; Cuello AC; Rosa-Neto P J Neurosci; 2017 Dec; 37(50):12263-12271. PubMed ID: 29097597 [TBL] [Abstract][Full Text] [Related]
9. Alzheimer's biomarker initiative hits its stride. Miller G Science; 2009 Oct; 326(5951):386-9. PubMed ID: 19833956 [No Abstract] [Full Text] [Related]
10. Structural magnetic resonance imaging in established and prodromal Alzheimer disease: a review. Atiya M; Hyman BT; Albert MS; Killiany R Alzheimer Dis Assoc Disord; 2003; 17(3):177-95. PubMed ID: 14512832 [No Abstract] [Full Text] [Related]
11. Neuroimaging outcomes for clinical trials. Frisoni GB; Caroli A J Nutr Health Aging; 2007; 11(4):348-52. PubMed ID: 17653497 [TBL] [Abstract][Full Text] [Related]
12. Longitudinal MR imaging in Alzheimer disease: a study anyone can join. Bizzi A Radiology; 2011 Mar; 258(3):657-9. PubMed ID: 21339344 [No Abstract] [Full Text] [Related]
13. Magnetic resonance approaches to brain aging and Alzheimer disease-associated neuropathology. Anderson VC; Litvack ZN; Kaye JA Top Magn Reson Imaging; 2005 Dec; 16(6):439-52. PubMed ID: 17088693 [TBL] [Abstract][Full Text] [Related]
14. Knowing the natural course of biomarkers in AD: longitudinal MRI, CSF and PET data. Van Der Flier WM; Scheltens P J Nutr Health Aging; 2009 Apr; 13(4):353-5. PubMed ID: 19300878 [No Abstract] [Full Text] [Related]
16. Methods for discerning disease-modifying effects in Alzheimer disease treatment trials. Kaye JA Arch Neurol; 2000 Mar; 57(3):312-4. PubMed ID: 10714654 [No Abstract] [Full Text] [Related]
17. The search for neuroimaging biomarkers of Alzheimer's disease with advanced MRI techniques. Li TQ; Wahlund LO Acta Radiol; 2011 Mar; 52(2):211-22. PubMed ID: 21498351 [TBL] [Abstract][Full Text] [Related]
18. Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD. Wan HI; Jacobsen JS; Rutkowski JL; Feuerstein GZ Clin Transl Sci; 2009 Jun; 2(3):242-7. PubMed ID: 20443898 [No Abstract] [Full Text] [Related]
19. Clinical use of brain volumetry. Giorgio A; De Stefano N J Magn Reson Imaging; 2013 Jan; 37(1):1-14. PubMed ID: 23255412 [TBL] [Abstract][Full Text] [Related]
20. Recruitment methods for United States Alzheimer disease prevention trials. Schneider LS J Nutr Health Aging; 2012 Apr; 16(4):331-5. PubMed ID: 22499452 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]